Healthcare >> CEO Interviews >> October 3, 2014
J. Michael French is President, CEO and Chairman of the board of Marina Biotech, Inc. Mr. French joined Marina Biotech in June 2008 as Chief Executive Officer. He became a director in September 2008, President in October 2008 and Chairman in August 2012. Mr. French was Senior Vice President of Corporate Development at Sirna Therapeutics from 2005 until 2007 when the company was acquired by Merck. Sirna was well-known as one of the leading RNAi companies. Earlier, Mr. French was Chief Business Officer at Entelos, Inc., a pre-IPO biotechnology company, as well as a variety of other positions at health care companies, including Health IQ and Bayer Pharmaceuticals. He also served for 13 years in the United States Army and Army Reserve. Mr. French holds an M.S. degree in physiology and biophysics from Georgetown University and a B.S. degree in aerospace engineering from the United States Military Academy. Profile
Mr. French: The company is a nucleic acids therapeutics company. We differentiate ourselves within the
